| Identification | Back Directory | [Name]
A-385358 | [CAS]
406228-55-5 | [Synonyms]
A-385358
Paclitaxel Impurity 60
(S)-N-(4-(4-(dimethylamino)-1-(phenylthio)butan-2-ylamino)-3-nitrophenylsulfonyl)-4-(4,4-dimethylpiperidin-1-yl)benzamide
Benzamide, N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-4-(4,4-dimethyl-1-piperidinyl)- | [Molecular Formula]
C32H41N5O5S2 | [MDL Number]
MFCD27665473 | [MOL File]
406228-55-5.mol | [Molecular Weight]
639.83 |
| Chemical Properties | Back Directory | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (195.36 mM) | [form ]
Solid | [pka]
3.71±0.10(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
A-385358, is a selective inhibitor of Bcl-XL with Kis, in vitro. In vivo, A-385358, in combination with the lower dose of paclitaxel produces a significant reduction in tumor growth (%T/C) compare with paclitaxel monotherapy. | [in vivo]
The combination of A-385358 given at 100 mg/kg/d plus the lower dose of paclitaxel produces a significant reduction in tumor growth (%T/C) compare with paclitaxel monotherapy. This combination also yields a >100% increase in time for tumors to reach 900 mm3 (%ILS) compare with vehicle control. Maximal efficacy is observed during the dosing period for A-385358, with slow but steady increase in the tumor growth after termination of treatment. The combination of A-385358 at 75 mg/kg/d plus paclitaxel at 30 mg/kg/d is also well tolerated and inhibits tumor growth rate by nearly 80%. Significant effects on tumor growth relative to paclitaxel monotherapy are observed with doses as low as 50 mg/kg/d[1]. | [IC 50]
Bcl-xL: 0.8 nM (Ki); Bcl-2: 67 nM (Ki) |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|